Biomarkers in IGA Nephropathy

References

• D’Amico G . Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am. J. Kidney Dis.36(2), 227–237 (2000).
   PubMed Web of Science ®Google Scholar
• Chauveau D , DrozD. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib. Nephrol.104, 1–5 (1993).
   PubMedGoogle Scholar
• Szeto CC , LaiFM, ToKFet al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am. J. Med.110(6), 434–437 (2001).
   PubMed Web of Science ®Google Scholar
• Shen P , HeL, LiY, WangY, ChanM. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron. Clin. Pract.106(4), c157–c161 (2007).
   PubMedGoogle Scholar
• Imai H , MiuraN. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission?Clin. Exp. Nephrol.16(2), 195–201 (2012).
   PubMed Web of Science ®Google Scholar
• Coppo R , D’AmicoG. Factors predicting progression of IgA nephropathies. J. Nephrol.18(5), 503–512 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki K , HondaK, TanabeKet al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int.63(6), 2286–2294 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki H , FanR, ZhangZet al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest.119(6), 1668–1677 (2009).
   PubMed Web of Science ®Google Scholar
• Novak J , JulianBA, TomanaM, MesteckyJ. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin. Nephrol.28(1), 78–87 (2008).
   PubMed Web of Science ®Google Scholar
• Barratt J , FeehallyJ. IgA nephropathy. J. Am. Soc. Nephrol.16(7), 2088–2097 (2005).
   PubMed Web of Science ®Google Scholar
• D’Amico G . Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin. Nephrol.24(3), 179–196 (2004).
   PubMed Web of Science ®Google Scholar
• Donadio JV and GrandeJP. IgA nephropathy. N. Engl. J. Med.347(10), 738–748 (2002).
   PubMed Web of Science ®Google Scholar
• Maeda A , GohdaT, FunabikiKet al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J. Clin. Lab. Anal.17(3), 73–76 (2003).
   PubMed Web of Science ®Google Scholar
• Kalantari S , RutishauserD, SamavatSet al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS ONE8(12), e80830 (2013).
   PubMed Web of Science ®Google Scholar
• Stangou M , PapagianniA, BantisCet al. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine. Clin. Nephrol.80(3), 203–210 (2013).
   PubMed Web of Science ®Google Scholar
• Liu L , ZhangY, DuanXet al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J. Clin. Immunol.34(2), 224–232 (2014).
   PubMed Web of Science ®Google Scholar
• Coppo R , AmoreA, PeruzziL, VerganoL, CamillaR. Innate immunity and IgA nephropathy. J. Nephrol.23(6), 626–632 (2010).
   PubMed Web of Science ®Google Scholar
• Liu LL , JiangY, WangLN, and LiuN. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin. Exp. Immunol.169(2), 148–155 (2012).
   PubMed Web of Science ®Google Scholar
• Surin B , SachonE, RougierJPet al. LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy. Proteomics13(1), 142–152 (2013).
   PubMed Web of Science ®Google Scholar
• Bakker WW , van DaelCM, PierikLJet al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr. Nephrol.20(10), 1410–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Lundberg S , GunnarssonI, JacobsonSH. Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy. Scand. J. Urol. Nephrol.46(2), 148–155 (2012).
   PubMed Web of Science ®Google Scholar
• Jackson D , CravenRA, HutsonRCet al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res.13(24), 7370–7379 (2007).
   PubMed Web of Science ®Google Scholar
• Humphries JM , PennoMA, WeilandFet al. Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim. Biophys. Acta1844(5), 1051–1058 (2014).
   PubMed Web of Science ®Google Scholar
• Khositseth S , KanitsapN, WarnnissornN, ThongboonkerdV. IgA nephropathy associated with Hodgkin’s disease in children: a case report, literature review and urinary proteome analysis. Pediatr. Nephrol.22(4), 541–546 (2007).
   PubMed Web of Science ®Google Scholar
• Moon PG , LeeJE, YouSet al. Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics11(12), 2459–2475 (2011).
   PubMed Web of Science ®Google Scholar
• Yanagawa H , SuzukiH, SuzukiYet al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS ONE9(5), e98081 (2014).
   PubMed Web of Science ®Google Scholar
• Suzuki Y , MatsuzakiK, SuzukiHet al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin. Exp. Nephrol.18(5) 770–777 (2014).
   PubMed Web of Science ®Google Scholar
• Meng H , ZhangL, EXet al. Application of Oxford classification, and overexpression of transforming growth factor-beta1 and immunoglobulins in immunoglobulin A nephropathy: correlation with World Health Organization classification of immunoglobulin A nephropathy in a Chinese patient cohort. Transl Res.163(1), 8–18 (2014).
   PubMed Web of Science ®Google Scholar
• Hastings MC , MoldoveanuZ, JulianBAet al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin. J. Am. Soc. Nephrol.5(11), 2069–2074 (2010).
   PubMed Web of Science ®Google Scholar
• Hastings MC , MoldoveanuZ, SuzukiHet al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin. Med. Diagn.7(6), 615–627 (2013).
   PubMedGoogle Scholar
• Zhao N , HouP, LvJet al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int.82(7), 790–796 (2012).
   PubMed Web of Science ®Google Scholar
• Takahashi K , RaskaM, Stuchlova HorynovaMet al. Enzymatic sialylation of IgA1 o-glycans: implications for studies of IgA nephropathy. PLoS ONE9(2), e99026 (2014).
   PubMedGoogle Scholar
• Takahashi K , SmithAD, PoulsenKet al. Naturally occurring structural isomers in serum IgA1 o-glycosylation. J. Proteome Res.11(2), 692–702 (2012).
   PubMed Web of Science ®Google Scholar
• Suzuki H , RaskaM, YamadaKet al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J. Biol. Chem.289(8), 5330–5339 (2014).
   PubMed Web of Science ®Google Scholar
• Iwatani H , InoueT, WadaYet al. Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy. Biochem. Biophys. Res. Commun.428(3), 339–342 (2012).
   PubMed Web of Science ®Google Scholar
• Sogabe A , UtoH, KanmuraSet al. Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy. Int. J. Mol. Med.32(2), 307–314 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang J , WangC, TangYet al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. Nephrology (Carlton)18(2), 125–131 (2013).
   PubMed Web of Science ®Google Scholar
• Kim SJ , KooHM, LimBJet al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One7(7), e40495 (2012).
   PubMed Web of Science ®Google Scholar
• Zivkovic AM , YangJ, GeorgiKet al. Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics8(6), 1102–1113 (2012).
   PubMed Web of Science ®Google Scholar
• Delanghe SE , SpeeckaertMM, SegersHet al. Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schonlein purpura nephritis. Clin. Biochem.46 (7–8), 591–597 (2013).
   PubMed Web of Science ®Google Scholar
• Doench JG , SharpPA. Specificity of microRNA target selection in translational repression. Genes Dev.18(5), 504–511 (2004).
   PubMed Web of Science ®Google Scholar
• Ju T , BrewerK, D’SouzaA, CummingsRD, CanfieldWM. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J. Biol. Chem.277(1), 178–186 (2002).
   PubMed Web of Science ®Google Scholar
• Hiki Y , OdaniH, TakahashiMet al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int.59(3), 1077–1085 (2001).
   PubMed Web of Science ®Google Scholar
• Tomana M , MatousovicK, JulianBAet al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int.52(2), 509–516 (1997).
   PubMed Web of Science ®Google Scholar
• Tomana M , NovakJ, JulianBAet al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J. Clin. Invest.104(1), 73–81 (1999).
   PubMed Web of Science ®Google Scholar
• Serino G , SallustioF, CoxSN, PesceF, SchenaFP. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J. Am. Soc. Nephrol.23(5), 814–824 (2012).
   PubMed Web of Science ®Google Scholar
• Cox SN , SallustioF, SerinoGet al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int.78(4), 396–407 (2010).
   PubMed Web of Science ®Google Scholar
• Tan K , ChenJ, LiWet al. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome56(3), 161–169 (2013).
   PubMed Web of Science ®Google Scholar
• Bao H , ChenH, ZhuXet al. MiR-223 downregulation promotes glomerular endothelial cell activation by upregulating importin alpha4 and alpha5 in IgA nephropathy. Kidney Int.85(3), 624–635 (2014).
   PubMed Web of Science ®Google Scholar
• Wang G , KwanBC, LaiFMet al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers28(2), 79–86 (2010).
   PubMed Web of Science ®Google Scholar
• Wang G , KwanBC, LaiFMet al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers30(4), 171–179 (2011).
   PubMed Web of Science ®Google Scholar
• Wang G , KwanBC, LaiFMet al. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am. J. Nephrol.36(5), 412–418 (2012).
   PubMed Web of Science ®Google Scholar
• Szeto CC , Ching-HaKB, Ka-BikLet al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers33(3), 137–144 (2012).
   PubMed Web of Science ®Google Scholar
• Suzuki H , KirylukK, NovakJet al. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol.22(10), 1795–1803 (2011).
   PubMed Web of Science ®Google Scholar
• Singh A , SatchellSC, NealCRet al. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J. Am. Soc. Nephrol.18(11), 2885–2893 (2007).
   PubMed Web of Science ®Google Scholar
• Ebefors K , GranqvistA, IngelstenMet al. Role of glomerular proteoglycans in IgA nephropathy. PLoS One6(4), e18575 (2011).
   PubMed Web of Science ®Google Scholar
• Villanueva S , ContrerasF, TapiaAet al. Basic fibroblast growth factor reduces functional and structural damage in chronic kidney disease. Am. J. Physiol. Renal. Physiol.306(4), F430–F441 (2014).
   PubMed Web of Science ®Google Scholar
• Salmivirta M , LidholtK, LindahlU. Heparan sulfate: a piece of information. FASEB J.10(11), 1270–1279 (1996).
   PubMed Web of Science ®Google Scholar
• Medical Physiology (2nd Edition). Boron WF , BoulpaepEL (Eds). Elsevier, PA, USA, 1337 (2012).
   Google Scholar
• Hill GS , KarouiKE, KarrasAet al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int.79(6), 635–642 (2011).
   PubMed Web of Science ®Google Scholar
• Lai KN , LeungJC, ChanLYet al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol. Dial. Transplant.24(1), 62–72 (2009).
   PubMed Web of Science ®Google Scholar
• Tian J , WangHP, MaoYY, JinJ, ChenJH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J. Int. Med. Res.35(3), 338–345 (2007).
   PubMed Web of Science ®Google Scholar
• Xu L , YangHC, HaoCMet al. Podocyte number predicts progression of proteinuria in IgA nephropathy. Mod. Pathol.23(9), 1241–1250 (2010).
   PubMed Web of Science ®Google Scholar
• Choi SY , SuhKS, ChoiDE, LimBJ. Morphometric analysis of podocyte foot process effacement in IgA nephropathy and its association with proteinuria. Ultrastruct. Pathol.34(4), 195–198 (2010).
   PubMed Web of Science ®Google Scholar
• Kodama F , AsanumaK, TakagiMet al. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Nephrol. Dial. Transplant.28(7), 1762–1772 (2013).
   PubMed Web of Science ®Google Scholar
• Asanuma K , CampbellKN, KimK, FaulC, MundelP. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc. Natl Acad. Sci. USA104(24), 10134–10139 (2007).
   PubMed Web of Science ®Google Scholar
• Qiu LQ , SinniahR, IHHS. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy. J. Am. Soc. Nephrol.15(1), 79–90 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou XJ , ChengFJ, QiYYet al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS ONE8(4), e61208 (2013).
   PubMed Web of Science ®Google Scholar
• Liu LL , LiuN, ChenYet al. Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. Clin. Exp. Immunol.174(1), 152–160 (2013).
   PubMed Web of Science ®Google Scholar
• Berthelot L , PapistaC, MacielTTet al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med.209(4), 793–806 (2012).
   PubMed Web of Science ®Google Scholar
• Snoeck V , PetersIR, CoxE. The IgA system: a comparison of structure and function in different species. Vet. Res.37(3), 455–467 (2006).
   PubMed Web of Science ®Google Scholar
• Launay P , GrosseteteB, Arcos-FajardoMet al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J. Exp. Med.191(11), 1999–2009 (2000).
   PubMed Web of Science ®Google Scholar
• Moura IC , CentellesMN, Arcos-FajardoMet al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J. Exp. Med.194(4), 417–425 (2001).
   PubMed Web of Science ®Google Scholar
• Moura IC , Arcos-FajardoM, SadakaCet al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J. Am. Soc. Nephrol.15(3), 622–634 (2004).
   PubMed Web of Science ®Google Scholar
• Moura IC , Arcos-FajardoM, GdouraAet al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J. Am. Soc. Nephrol.16(9), 2667–2676 (2005).
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F , RavetchJV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol.8(1), 34–47 (2008).
   PubMed Web of Science ®Google Scholar
• Szeto CC and LiPK. MicroRNAs in IgA nephropathy. Nat. Rev. Nephrol.10(5), 249–256 (2014).
   PubMed Web of Science ®Google Scholar
• Fang Y , YuX, LiuYet al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am. J. Physiol. Renal. Physiol.304(10), F1274–F1282 (2013).
   PubMed Web of Science ®Google Scholar
• Bjornson Granqvist A , EbeforsK, SaleemMAet al. Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am. J. Physiol. Renal. Physiol.291(4), F722–F730 (2006).
   PubMed Web of Science ®Google Scholar
• Wang W , QiuL, HowardAet al. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. doi:10.1177/1470320313507123 (2014) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Zhao S , GuX, GroomeLJ, WangY. Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia. Reprod. Sci.16(10), 970–979 (2009).
   PubMed Web of Science ®Google Scholar
• Qin W , ChungAC, HuangXRet al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol.22(8), 1462–1474 (2011).
   PubMed Web of Science ®Google Scholar